Opinion

Video

1L treatment of lower-risk MDS beyond luspatercept

Author(s):

Guillermo Garcia-Manero, MD,Rami Komrokji, MD

Medical experts explore alternative treatment options for lower-risk myelodysplastic syndrome (LR-MDS) patients who are not suitable candidates for first-line luspatercept therapy.

  1. For patients who are not suitable to receive 1L luspatercept for LR-MDS, what alternate treatment options would you consider?
  2. What other trials on the horizon are you excited for in the 1L treatment of lower-risk MDS?
Related Videos
2 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment
September 15th 2021

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment